#153540

Anti-phospho-Sufu

Please Enter Your Email ID
Email ID

Cat. #153540

Anti-phospho-Sufu

Cat. #: 153540

Sub-type: Primary antibody

Unit size: 100 ug

Target: Sufu (UniProt ID: Q9UMX1)

Class: Polyclonal

Application: IF ; WB

Reactivity: Human ; Mouse

Host: Rabbit

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Vincenzo D'Angiolella

Institute: University of Oxford

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-phospho-Sufu
  • Alternate name: Suppressor of fused homolog, SUFUH
  • Research fields: Cancer;Developmental biology;Genetics
  • Tool sub type: Primary antibody
  • Class: Polyclonal
  • Conjugation: Unconjugated
  • Cell signalling pathway: Hedgehog
  • Molecular weight: ~65 kDa
  • Reactivity: Human ; Mouse
  • Host: Rabbit
  • Application: IF ; WB
  • Description: Anti-phospho-Sufu polyclonal antibody recognises wild type sufu which is phosphorylated at serine 352. The antibody specificity for the phosphorylated version has been confirmed; it does not react against a non-phosphorylated version of Sufu which has serine 352 substituted by alanine. Sufu is a negative regulator in the hedgehog signaling pathway which directs cell proliferation and patterning during embryogenesis. Sufu down-regulates GLI1- and GLI2-mediated transactivation of target genes and is part of a corepressor complex that acts on DNA-bound GLI1. Required for normal embryonic development. Sufu is ubiquitous in adult tissues. Heterozygous loss of Sufu, in conjunction with the loss of p53, leads to the development of medulloblastoma and rhabdomyosarcoma. Somatic Sufu mutations have been identified in multiple other malignancies, including prostate cancer.
  • Immunogen: Sufu peptide: Hu #347~360: CLESDS-pS-pT-AIIPHEL

Target Details

  • Target: Sufu (UniProt ID: Q9UMX1)
  • Molecular weight: ~65 kDa
  • Target background: Anti-phospho-Sufu polyclonal antibody recognises wild type sufu which is phosphorylated at serine 352. The antibody specificity for the phosphorylated version has been confirmed; it does not react against a non-phosphorylated version of Sufu which has serine 352 substituted by alanine. Sufu is a negative regulator in the hedgehog signaling pathway which directs cell proliferation and patterning during embryogenesis. Sufu down-regulates GLI1- and GLI2-mediated transactivation of target genes and is part of a corepressor complex that acts on DNA-bound GLI1. Required for normal embryonic development. Sufu is ubiquitous in adult tissues. Heterozygous loss of Sufu, in conjunction with the loss of p53, leads to the development of medulloblastoma and rhabdomyosarcoma. Somatic Sufu mutations have been identified in multiple other malignancies, including prostate cancer.

Applications

  • Application: IF ; WB

Handling

  • Format: Liquid
  • Concentration: 2 mg/ml
  • Unit size: 100 ug
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

Related Tools

  • Related tools: Anti-Sufu, Polyclonal

References

  • Raducu et al. 2016. EMBO J. 35(13):1400-16. PMID: 27234298.
  • SCF (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma development.